There are two clinical types of age-related macular degeneration: atrophic (dry) and exudative (wet). Wet macular degeneration is characterized by the formation of subretinal neovascularization (CNV), which causes a series of fundus changes such as hemorrhage, edema, exudation and scar formation in the macula. In the early stage, it may manifest as blurring of objects and distortion of vision. When there is hemorrhage and exudation, the central vision can be drastically reduced. In the late stage, the lesion ends with scar formation and the patient loses central vision. Therefore, wet macular degeneration can cause dramatic and severe damage to vision. In terms of clinical treatment, wet macular degeneration has been a clinical challenge in ophthalmology. Although photodynamic therapy can control the development of the lesion to a certain extent and slow down the degree of visual impairment, there is little improvement in visual acuity after treatment. However, the emergence of anti-VEGF drug vitreous injection treatment technology brings light and hope to patients with wet macular degeneration. Anti-VEGF drugs are a class of drugs that have antagonistic effects on vascular endothelial growth factor. The most used drugs internationally are AVASTIN (Avastin) and LUCENTIS (Ranibizumab). It was first used for wet macular degeneration in 2006, and in recent years its indications have been expanded to include retinal vein obstruction and diabetic macular edema. This year, Ranibizumab (trade name Noxid) was officially launched in China as a treatment for wet macular degeneration, enabling Chinese patients with wet macular degeneration to enjoy this latest medical technology. The mechanism of Ranibizumab (Noxid) for wet macular degeneration is to prevent the growth of choroidal neovascularization by antagonizing vascular endothelial growth factor, causing it to atrophy, and to reduce retinal edema and exudation by down-regulating inflammatory factors. The treatment of wet macular degeneration with intravitreal injection of ranibizumab often improves visual acuity while effectively controlling the lesion. Therefore, this treatment technique is classified as the first-line treatment for wet macular degeneration. The recommended treatment for wet macular degeneration with intravitreal injections of Ranibizumab (Norvasc) is once a month for 3 consecutive injections, followed by monthly review and repeat treatment based on visual acuity and OCT findings. In our clinical observation, even 1-2 vitreous injections in early stage cases can achieve satisfactory results. The vitreous injection treatment with ranibizumab is safe and no side effects of the drug itself have been found in clinical studies. However, it is still necessary to strictly follow the treatment requirements to prevent complications related to vitreous injection, such as infection, hemorrhage and retinal detachment.